TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...
TipRanks on MSN
PharmAla Biotech posts rising deposits as LaNeo MDMA demand builds and Australian trial plans advance
PharmAla Biotech Holdings, Inc. ( ($TSE:MDMA) ) just unveiled an update. PharmAla Biotech Holdings has released its audited financial statements ...
TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla ” or the “Company ”) (CSE: MDMA) (OTCQB:MDXXF), a biotechnology company focused on the research, development, and ...
“Following our news from March of our successful delivery of LaNeo™ MDMA for a trial at the University of Washington, this is the second new pilot study with a novel indication for MDMA enabled by ...
TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...
Year End 2025 – an increase of $150k offset by recognized revenue of $83k, resulting in $276k compared to $209k as at August 31, 2025 and 2024, respectively. Q1 2026 – increase of $225k, offset by ...
TORONTO, April 05, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback